TGF-β2-targeted therapies are currently evaluated in randomised clinical trials (Fakhrai et al., 2006; Schlingensiepen et al, 2006) in consistent with the reports on the relevance of TGF-β2 for the progression of high-grade gliomas. Here, TGFB2 is linked to central nervous system cancer.